The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Inclusion Criteria:

• Participants may be without type 2 diabetes (T2D), or with T2D if their hemoglobinA1c (HbA1c) is 10% or lower

• Participants have established atherosclerotic cardiovascular disease (ASCVD) and/orchronic kidney disease (CKD), as evidenced at least one of the following:

• Coronary artery disease

• Cerebrovascular disease

• Peripheral arterial disease

• Chronic kidney disease defined as:

• eGFR <45 millilitres/minute/1.73 meter squared (mL/min/1.73m^2) and UACR >30 milligram/gram (mg/g) (0.030 mg/mg)

• eGFR <60 mL/min/1.73 m^2 and UACR >100 mg/g (0.100 mg/mg), or

• eGFR <75 mL/min/1.73 m^2 and UACR >300 mg/g (0.300 mg/mg) (eGFR iscalculated by central lab based on Chronic Kidney Disease EpidemiologyCollaboration (CKD-EPI) creatinine-cystatin c equation as determined bycentral lab)

• A Body Mass Index of ≥27.0 kilograms per meter squared (kg/m^2)

Exclusion Criteria:

Diabetes related:

• Participants have Type 1 Diabetes or any history of diabetic ketoacidosis

CV related:

• Participants have any of the following cardiovascular conditions ≤ 90 days prior torandomization:

• Myocardial infarction

• Acute coronary syndrome

• Stroke, or

• Coronary, peripheral, or carotid artery arterial revascularization procedure.

• Have acute decompensated heart failure requiring hospitalization.

• Have New York Heart Association (NYHA) Classification Class IV heart failure atscreening

Kidney related:

• Participants have an eGFR <20 mL/min/1.73 m^2 at screening

• Have UACR >5000 mg/g (5.000 mg/mg) at screening

• Have received any form of dialysis ≤ 90 days from the date of randomization

• Have either undergone a kidney transplant or have a transplant procedure scheduled

Other medical conditions:

• Participants have had or plan to have a surgical treatment for obesity,

• Have a history of chronic or acute pancreatitis

• Have a family or personal history of medullary thyroid carcinoma or multipleendocrine neoplasia (MEN) syndrome type 2

• Have a known clinically significant gastric emptying abnormality, such as severegastroparesis or gastric outlet obstruction